Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade F 19.3 0.31% 0.06
EXEL closed up 0.31 percent on Monday, September 16, 2019, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical EXEL trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
180 Bearish Setup Bearish Swing Setup 0.21%
Oversold Stochastic Weakness 0.21%
NR7 Range Contraction -0.57%
Oversold Stochastic Weakness -0.57%
Stochastic Buy Signal Bullish 0.21%
Oversold Stochastic Weakness 0.21%
Oversold Stochastic Weakness 1.58%
NR7 Range Contraction 0.16%

Older signals for EXEL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Protein Kinase Inhibitor Genentech Metastatic Castration Resistant Prostate Cancer Small Molecule Therapies
Is EXEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 25.31
52 Week Low 13.42
Average Volume 2,467,411
200-Day Moving Average 21.2945
50-Day Moving Average 20.43
20-Day Moving Average 19.87
10-Day Moving Average 19.336
Average True Range 0.7191
ADX 17.3
+DI 15.4072
-DI 25.841
Chandelier Exit (Long, 3 ATRs ) 20.6627
Chandelier Exit (Short, 3 ATRs ) 20.7173
Upper Bollinger Band 21.8176
Lower Bollinger Band 17.9224
Percent B (%b) 0.35
BandWidth 19.603422
MACD Line -0.3682
MACD Signal Line -0.3561
MACD Histogram -0.0121
Fundamentals Value
Market Cap 5.67 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 96.50
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.90
Resistance 3 (R3) 19.88 19.66 19.80
Resistance 2 (R2) 19.66 19.51 19.67 19.77
Resistance 1 (R1) 19.48 19.41 19.57 19.50 19.73
Pivot Point 19.26 19.26 19.31 19.27 19.26
Support 1 (S1) 19.08 19.11 19.17 19.10 18.87
Support 2 (S2) 18.86 19.01 18.87 18.83
Support 3 (S3) 18.68 18.86 18.80
Support 4 (S4) 18.70